Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line bevacizumab with carboplatin and paclitaxel in advanced epithelial ovarian cancer: prognostic factors study
2012-003043-29Phase 4Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Sep 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab, carboplatin and paclitaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoints: Progression-free survival and Overall survival. Started Sep 2012; status: completed.
02
Drugs
bevacizumabcarboplatinpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2012-003043-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003043-29.